In actual tumor therapy, the single immune function of CD8+ cells is not enough to destroy tumor cells, as the immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4) are only 30% effective (Gellrich et al., 2020). The gene discussed is CD8A; the disease is neoplasm.